MBX Biosciences, Inc.
MBXHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, MBX Biosciences, Inc. focuses on Biotechnology services and products. MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. With a market capitalization of $2.34B, it sits in mid-cap territory. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Market Cap
$2.34B
Beta
0.10
P/E (TTM)
—
P/E (Fwd)
-12.20
EPS (TTM)
$-2.37
EPS (Fwd)
$-3.98
ROE
-33.2%
ROA
-22.1%
Cash
$418.6M
Total Debt
$3.3M
Free CF
-$53.0M
52W Change
178.1%
Annual Financials
Cash vs Debt
Where MBX stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, MBX finished 3.96% above its 150-day moving average ($47.72) and 11.23% above its 200-day moving average ($44.60). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MBX overbought or oversold?
At the October 19, 2026 close, MBX's RSI(14) was 27.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $418.6M in cash comfortably exceeding the $3.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$53.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -33.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.10 suggests MBX is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, MBX has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MBX.